016580 — Whanin Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapTurnaround

Annual income statement for Whanin Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	177,776	198,935	230,394	259,596	255,214
Cost of Revenue
Gross Profit	93,492	98,793	99,161	93,776	87,099
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	146,500	169,124	200,223	238,101	242,196
Operating Profit	31,276	29,810	30,170	21,495	13,019
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	33,882	29,808	33,793	26,947	14,926
Provision for Income Taxes
Net Income After Taxes	26,459	23,734	29,774	23,381	13,595
Minority Interest
Net Income Before Extraordinary Items
Net Income	26,660	23,921	29,774	23,381	13,595
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	26,660	23,921	29,774	23,381	13,595
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,747	1,666	2,017	1,550	874
Dividends per Share